MP Outlook – 2021 and Beyond
At the threshold of this New Year, we are pleased to share the ‘MP Outlook – 2021 and Beyond’ (link to the presentation) where we present our analyses on some of the high-impact areas potentially reshaping BioPharma industry, especially from the learnings due to the pandemic. Some of the key highlights of the presentation are – BioPharma can no longer afford to spend a decade and a billion dollar in getting a drug to the market. Integration of AI-based platform…